Tag: katsanos
Paclitaxel puzzles: Final word on the controversy
Following his statement titled ‘Paclitaxel meta-analyses in the lower limbs: Missing the trees for the forest’ published in the June issue of The Journal...
Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception
“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons in the peripheral arteries,” findings from a systematic review...
Real-world data with long-term follow-up confirm no increased mortality signal with...
Data from an unselected, real-world cohort of 64,000 claimants of the German BARMER Health Insurance reveals no signal of increased long-term mortality when paclitaxel-based...
VEITH 2019: “Light at the end of the tunnel” following paclitaxel...
Sean Lyden (Cleveland, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about the “tumultuous” year for the industry following the publication of the...
SWEDEPAD trials set to resume enrolment
Investigators of SWEDEPAD have announced the conclusion of their safety committee analysis, which recommends the halted trials resume enrolment.
This decision to consider resuming enrolment...
Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical...
Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...
